Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher rates of remission compared with calorie restriction alone, finds a trial published by The BMJ today.
Multiple Sclerosis Predicted by Autoantibody Signature
A specific autoantibody signature was seen in a subset of people with multiple sclerosis (MS) long before clinical symptoms appeared, blood samples showed. A distinct
April 20, 2024